Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q411588> ?p ?o }
Showing triples 1 to 59 of
59
with 100 triples per page.
- Q411588 subject Q6814492.
- Q411588 subject Q7210776.
- Q411588 subject Q7215865.
- Q411588 subject Q8301176.
- Q411588 subject Q9052781.
- Q411588 abstract "Eltrombopag (rINN, codenamed SB-497115-GR) is a medication that has been developed for conditions that lead to thrombocytopenia (abnormally low platelet counts). It is a small molecule agonist of the c-mpl (TpoR) receptor, which is the physiological target of the hormone thrombopoietin. Eltrombopag was discovered as a result of research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals. Designated an orphan drug in the USA and European Union, it is being manufactured and marketed by GlaxoSmithKline under the trade name Promacta in the USA and is marketed as Revolade in the EU. Eltrombopag was approved by the U.S. Food and Drug Administration on November 20, 2008. Eltrombopag received FDA breakthrough treatment designation in February 2014 for patients with aplastic anemia for which immunosuppression has not been successful. It has been shown to produce a trilineage hematopoesis in some patients with aplastic anemia, resulting in increased platelet counts, along with red and white blood cell counts.".
- Q411588 atcPrefix "B02".
- Q411588 atcSuffix "BX05".
- Q411588 casNumber "496775-61-2".
- Q411588 casSupplemental "(olamine)".
- Q411588 fdaUniiCode "S56D65XJ9G".
- Q411588 iupacName "3'-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazino}-2'-hydroxy-3-biphenylcarboxylic acid".
- Q411588 pubchem "9846180".
- Q411588 thumbnail Eltrombopag.svg?width=300.
- Q411588 wikiPageWikiLink Q101026.
- Q411588 wikiPageWikiLink Q11364.
- Q411588 wikiPageWikiLink Q12140.
- Q411588 wikiPageWikiLink Q1367466.
- Q411588 wikiPageWikiLink Q147778.
- Q411588 wikiPageWikiLink Q14890102.
- Q411588 wikiPageWikiLink Q14916190.
- Q411588 wikiPageWikiLink Q154869.
- Q411588 wikiPageWikiLink Q18029261.
- Q411588 wikiPageWikiLink Q188269.
- Q411588 wikiPageWikiLink Q204711.
- Q411588 wikiPageWikiLink Q208467.
- Q411588 wikiPageWikiLink Q21163356.
- Q411588 wikiPageWikiLink Q212322.
- Q411588 wikiPageWikiLink Q22079533.
- Q411588 wikiPageWikiLink Q30.
- Q411588 wikiPageWikiLink Q389934.
- Q411588 wikiPageWikiLink Q410387.
- Q411588 wikiPageWikiLink Q458.
- Q411588 wikiPageWikiLink Q585285.
- Q411588 wikiPageWikiLink Q638729.
- Q411588 wikiPageWikiLink Q6814492.
- Q411588 wikiPageWikiLink Q7210776.
- Q411588 wikiPageWikiLink Q7215865.
- Q411588 wikiPageWikiLink Q821701.
- Q411588 wikiPageWikiLink Q824258.
- Q411588 wikiPageWikiLink Q8301176.
- Q411588 wikiPageWikiLink Q846316.
- Q411588 wikiPageWikiLink Q902835.
- Q411588 wikiPageWikiLink Q9052781.
- Q411588 wikiPageWikiLink Q9368.
- Q411588 atcPrefix "B02".
- Q411588 atcSuffix "BX05".
- Q411588 casNumber "496775".
- Q411588 iupacName "3".
- Q411588 pubchem "9846180".
- Q411588 unii "S56D65XJ9G".
- Q411588 type ChemicalSubstance.
- Q411588 type Drug.
- Q411588 type ChemicalObject.
- Q411588 type Thing.
- Q411588 type Q8386.
- Q411588 comment "Eltrombopag (rINN, codenamed SB-497115-GR) is a medication that has been developed for conditions that lead to thrombocytopenia (abnormally low platelet counts). It is a small molecule agonist of the c-mpl (TpoR) receptor, which is the physiological target of the hormone thrombopoietin. Eltrombopag was discovered as a result of research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals.".
- Q411588 label "Eltrombopag".
- Q411588 depiction Eltrombopag.svg.